Literature DB >> 23719920

Detecting soluble polyQ oligomers and investigating their impact on living cells using split-GFP.

Patrick Lajoie1, Erik Lee Snapp.   

Abstract

Aberrant expansion of the number of polyglutamine (polyQ) repeats in mutant proteins is the hallmark of various diseases. These pathologies include Huntington's disease (HD), a neurological disorder caused by expanded polyQ stretch within the huntingtin (Htt) protein. The expansions increase the propensity of the Htt protein to oligomerize. In the cytoplasm of living cells, the mutant form of Htt (mHtt) is present as soluble monomers and oligomers as well as insoluble aggregates termed inclusion bodies (IBs). Detecting and assessing the relative toxicity of these various forms of mHtt has proven difficult. To enable direct visualization of mHtt soluble oligomers in living cells, we established a split superfolder green fluorescent protein (sfGFP) complementation assay. In this assay, exon 1 variants of Htt (Htt(ex1)) containing non-pathological or HD-associated polyQ lengths were fused to two different nonfluorescent fragments of sfGFP. If the Htt proteins oligomerize and the sfGFP fragments come into close proximity, they can associate and complement each other to form a complete and fluorescent sfGFP reporter. Importantly, the irreversible nature of the split-sfGFP complementation allowed us to trap otherwise transient interactions and artificially increase mHtt oligomerization. When coupled with a fluorescent apoptosis reporter, this assay can correlate soluble mHtt oligomer levels and cell death leading to a better characterization of the toxic potential of various forms of mHtt in living cells.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23719920      PMCID: PMC4112564          DOI: 10.1007/978-1-62703-438-8_17

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  15 in total

1.  Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death.

Authors:  Montserrat Arrasate; Siddhartha Mitra; Erik S Schweitzer; Mark R Segal; Steven Finkbeiner
Journal:  Nature       Date:  2004-10-14       Impact factor: 49.962

2.  Engineering and characterization of a superfolder green fluorescent protein.

Authors:  Jean-Denis Pédelacq; Stéphanie Cabantous; Timothy Tran; Thomas C Terwilliger; Geoffrey S Waldo
Journal:  Nat Biotechnol       Date:  2005-12-20       Impact factor: 54.908

3.  Determinism and divergence of apoptosis susceptibility in mammalian cells.

Authors:  Patrick D Bhola; Sanford M Simon
Journal:  J Cell Sci       Date:  2009-11-03       Impact factor: 5.285

4.  Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain.

Authors:  M DiFiglia; E Sapp; K O Chase; S W Davies; G P Bates; J P Vonsattel; N Aronin
Journal:  Science       Date:  1997-09-26       Impact factor: 47.728

Review 5.  Huntington's disease: seeing the pathogenic process through a genetic lens.

Authors:  James F Gusella; Marcy E MacDonald
Journal:  Trends Biochem Sci       Date:  2006-07-10       Impact factor: 13.807

6.  Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice.

Authors:  L Mangiarini; K Sathasivam; M Seller; B Cozens; A Harper; C Hetherington; M Lawton; Y Trottier; H Lehrach; S W Davies; G P Bates
Journal:  Cell       Date:  1996-11-01       Impact factor: 41.582

7.  Soluble polyglutamine oligomers formed prior to inclusion body formation are cytotoxic.

Authors:  Toshiaki Takahashi; Shinya Kikuchi; Shinichi Katada; Yoshitaka Nagai; Masatoyo Nishizawa; Osamu Onodera
Journal:  Hum Mol Genet       Date:  2007-10-18       Impact factor: 6.150

Review 8.  Polyglutamine neurodegeneration: protein misfolding revisited.

Authors:  Aislinn J Williams; Henry L Paulson
Journal:  Trends Neurosci       Date:  2008-09-06       Impact factor: 13.837

9.  Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat length.

Authors:  M W Becher; J A Kotzuk; A H Sharp; S W Davies; G P Bates; D L Price; C A Ross
Journal:  Neurobiol Dis       Date:  1998-04       Impact factor: 5.996

10.  Mouse models of Huntington disease: variations on a theme.

Authors:  Dagmar E Ehrnhoefer; Stefanie L Butland; Mahmoud A Pouladi; Michael R Hayden
Journal:  Dis Model Mech       Date:  2009 Mar-Apr       Impact factor: 5.758

View more
  3 in total

1.  Introducing inducible fluorescent split cholesterol oxidase to mammalian cells.

Authors:  Konstantin G Chernov; Maarit Neuvonen; Ivonne Brock; Elina Ikonen; Vladislav V Verkhusha
Journal:  J Biol Chem       Date:  2017-04-07       Impact factor: 5.157

Review 2.  The Molecular Basis of Spinocerebellar Ataxia Type 7.

Authors:  Rituparna Goswami; Abudu I Bello; Joe Bean; Kara M Costanzo; Bwaar Omer; Dayanne Cornelio-Parra; Revan Odah; Amit Ahluwalia; Shefaa K Allan; Nghi Nguyen; Taylor Shores; N Ahmad Aziz; Ryan D Mohan
Journal:  Front Neurosci       Date:  2022-03-24       Impact factor: 4.677

Review 3.  Huntington's Disease: Mechanisms of Pathogenesis and Therapeutic Strategies.

Authors:  Maria Jimenez-Sanchez; Floriana Licitra; Benjamin R Underwood; David C Rubinsztein
Journal:  Cold Spring Harb Perspect Med       Date:  2017-07-05       Impact factor: 6.915

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.